Research Article

Anti-Inflammatory Effects of Sosiho-Tang, a Traditional Herbal Formula, on Acute Lung Injury in LPS-Sensitized Mice and -Raw 264.7 Cells

La Yoon Choi,¹ Mi Hye Kim,¹ Da-Hwa Jung,² and Woong Mo Yang¹

¹Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
²National Development Institute of Korean Medicine, 288 Udeurandeu-gil, Sejong, Janheung-gun 59338, Republic of Korea

Correspondence should be addressed to Woong Mo Yang; wmyang@khu.ac.kr

Received 3 December 2020; Revised 21 January 2021; Accepted 29 January 2021; Published 9 February 2021

Academic Editor: Saeideh Saadat

Copyright © 2021 La Yoon Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute lung injury (ALI) is a series of syndromes with persistent inflammation and abnormally increased vascular permeability. Sosiho-tang (SSHT), a traditional herbal formula consisting of a mixture of seven herbs, has been used to treat allergic reactions and chronic hepatitis disease in East Asia. In this study, we determined whether SSHT has an inhibitory effect against lipopolysaccharide- (LPS-) induced acute lung injury (ALI) in mice. 0.05, 0.55, and 5.55 mg/kg of SSHT were orally administered to C57BL/6J mice for 7 days prior to the administration of LPS. After 2 h of LPS sensitization, lung tissues were collected to confirm the lung histology and ALI-related inflammatory factors. SSHT ameliorated the LPS-induced alveolar hemorrhage, alveolar wall thickening, and the shrinkage of the alveolar spaces in the ALI mice model. Proinflammatory cytokines including IL-6, TNF-α, and IFN-γ in the lung tissue were significantly regulated in the SSHT-treated groups compared to the LPS only-treated group. Also, increases of IL-6 and TNF-α and decrease of IFN-γ expressions were dose-dependently modulated by SSHT treatment in LPS-induced raw 264.7 cells. Additionally, the translocation of NF-κB into nucleus and phosphorylation of mitogen-activated protein (MAP) kinase were significantly attenuated by the treatment of SSHT in LPS-sensitized ALI mice. SSHT showed anti-inflammatory activities by inhibiting proinflammatory cytokines and NF-κB signaling in LPS-induced ALI. This study demonstrates that SSHT has preventive effects on LPS-induced ALI by regulating inflammatory responses as an alternative for treating lung diseases.

1. Introduction

Acute lung injury (ALI) is a life-threatening medical complication with a range from 52 to 65% of mortality rate in patients [1]. ALI is associated with sepsis, traumatic injuries, inhalation, massive blood transfusion, bilateral pulmonary infiltration, and hypoxemia [2]. It is commonly accompanied by systemic inflammatory responses following pulmonary edema, increase of alveolar capillary barrier permeability, and excessive cytokines production in lung [3–5]. In the previous studies, lipopolysaccharide (LPS), component of Gram-negative bacteria, has been known to induce the release of proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which stimulates alveolar hemorrhage, alveolar wall thickening, and alveolar spaces shrinkage [6, 7].

Clinically, treatment of ALI focuses on counterbalance of inflammatory response by regulating inflammatory/anti-inflammatory cytokines production [8]. Some studies have reported that methylprednisolone reduces ventilation, respiratory shock, and mortality rate in ALI patients by improving the systemic inflammatory response [9]. However, the efficacy of methylprednisolone, one of the representative corticosteroids, is controversial, because some studies reported no significant benefit on ALI in clinical trials [10, 11]. In addition, there were unexpected side effects of corticosteroids such as hyperglycemia, hypertension, and further severe neuronal disorder [12, 13]. Commonly, inhalation of
oxygen and restriction of intravenously received fluids are primary treatments for ALI; however, they may lead to pulmonary edema and interstitial pneumonitis due to the increase of pulmonary venous oxygenation caused by hyperoxia [14, 15]. Novel treatment derived from natural products with no side effects is required to treat ALI.

**Sosiho-tang**, known as Sho-saiko-to in Japanese and Xiao-Chai-Hu-Tang in Chinese, is an herbal medicine in Korea for medical insurance. **Sosiho-tang** consists of seven herbs: *Bupleurum falcatum* Linne 12 g, *Scutellaria baicalensis* Georgii 8 g, *Pinellia ternata* Breitenbach 4 g, *Panax ginseng* C. A. Meyer 4 g, *Glycyrrhiza glabra* Linn var. *glandulifera* Regel & Herder 2 g, 3 of *Ziziphus vulgaris* Roscoe, and 2 of *Ziziphus vulgaris* Lamarck var. *inermis* Bunge. It is widely used for treating allergic diseases, cold-related symptoms, and chronic liver disease [16–19]. In particular, diseases for which medicine is efficacious of **Sosiho-tang** include the dyshepatia and hepatitis of chronic liver disorders [20, 21]. In the preclinical studies, **Sosiho-tang** improved liver inflammation and fibrosis by regulating liver toxicity levels, demonstrating that research of **Sosiho-tang** is focused on liver disease [19, 22, 23]. Because **Sosiho-tang** is reported to decrease the production of T helper 2-type cytokines and chemokine [24], we postulated that **Sosiho-tang** has a therapeutic effect on ALI via its anti-inflammatory effects. In the present study, inflammatory effects of **Sosiho-tang** against ALI were determined in LPS-sensitized mice and raw 264.7 cells.

### 2. Materials and Methods

#### 2.1. Sosiho-Tang Soft Extract Sample.

The sample of **Sosiho-tang** used in this study was Jungwoo Pharmacy **Sosiho-tang Soft Ext.** (SSHT), a prescription-based medicine in Korea. SSHT, a Korean Medicine for national health insurance, was obtained from Jungwoo Pharmacy Co., Ltd. (Lot. no. 702). Briefly, SSHT consists of 750 mg of *Bupleurum falcatum* Linne, 1,115 g of *Scutellaria baicalensis* Georgii, 588 mg of *Pinellia ternata* Breitenbach, 514 mg of *Panax ginseng* C. A. Meyer, 246 mg of *Glycyrrhiza glabra* Linn var. *glandulifera* Regel & Herder, 75 mg of *Ziziphus officinale* Roscoe, and 518 mg of *Ziziphus vulgaris* Lamarck var. *inermis* Bunge soft extracts based on the general requirements in the Korean Pharmacopoeia. A total of 9 g of SSHT was dissolved in distilled water with appropriate doses for mice.

#### 2.2. Animal Treatment.

Thirty-six males C57BL/6 mice at 5 weeks of age were purchased from Raon Bio Inc. (Yongin, Korea). Mice were housed under controlled conditions (at 24 ± 2°C, relative humidity of 50–80%, and 12 h light/dark cycle). After 1-week acclimation, mice were randomly divided into six groups with 6 per group: CTR (nontreated group as a normal control), LPS (LPS-sensitized group as a negative control), DEX (LPS-sensitized and DEX-treated group as a positive control), SSHT 0.05 g/kg-treatment group), SSHT 0.55 g/kg-treatment group), and S5.55 (LPS-sensitized and SSHT 5.55 g/kg-treated group). 7 mg/kg of dexamethasone (DEX) and SSHT were orally preadministered for 1 week, followed by intraperitoneal injection of 10 mg/kg LPS. The SSHT that was used for the human being 9 g/60 kg/day was converted by using the human equivalent dose (HED) equation used for mice into 5.55 g/kg. There was no toxicity to mice during sample administration of SSHT 5.55 g/kg. Following LPS sensitization for 2 h, blood samples were collected by cardiac puncture. Lung tissues were collected at 10% neutralized formalin solution. All experiments were approved by the Committee on Care and Use of Laboratory Animals of Kyung Hee University (KHUASP(SE)-18-078; Seoul, Korea).

#### 2.3. Histological Analysis.

The right inferior lobe of lung was fixed at 10% neutralized formalin for 24 h. The lung tissues were dehydrated and embedded in paraffin for 24 h. The paraffin blocks were cut cross into 4 μm thickness and mounted on slides. These slides were stained with hematoxylin and eosin solution. The stained slides were photographed by digital microscope at a magnification of 200× and 400×. The blind test for ALI score was determined as 0 to 5 grades: 0, no injury and appears normal; 1, minimal (injury up to 25% of the field); 2, mild (injury between 25 and 50% of the field); 3, moderate (injury between 50 and 75% of the field); and 4, severe (>75%, diffuse injury). Tissue sections were examined by a pathologist blinded to the experiment.

#### 2.4. Cell Treatment.

Raw 264.7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% v/v fetal bovine serum (Gibco), 2 mM glutamine, 100 IU/ml penicillin, and 100 μg/mL streptomycin (Gibco). Cells were grown at 37°C in an atmosphere containing 5% CO₂ of 95% humidity. Cells were seeded in 6-well plates and treated with 1, 10, 100, 250, 500, and 1000 μg/mL of SSHT in the presence of LPS 1 μg/mL for 24 h. DEX was treated at the 1 μg/mL concentration to raw 264.7 cells for 24 h.

#### 2.5. Preparations of Protein Extracts.

Whole left lobe of lung tissues containing the left-upper lobe and the lower lobe was homogenized using a radioimmunoprecipitation assay (RIPA) lysis buffer (50 mm Tris-HCl, pH 7.4, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 150 mM NaCl) containing protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) for extracts of whole proteins. The lysed proteins were centrifuged at 15,928 g for 10 min at 4°C and collected supernatants were used to determine mitogen-activated protein (MAP) Kinase, ERK1/2, SAPK/JNK, and p38. To extract cytoplasmic proteins, frozen lung tissues were homogenized with cytoplasmic buffer (10 mM HEPES, pH 7.9, 20 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.15% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF, and 5 mM Na3VO4) containing the protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) for extracts of whole proteins. The proteins were centrifuged at 15,928 g for 10 min at 4°C and collected supernatant was used to determine mitogen-activated protein (MAP) Kinase, ERK1/2, SAPK/JNK, and p38. To extract cytoplasmic proteins, frozen lung tissues were homogenized with cytoplasmic buffer (10 mM HEPES, pH 7.9, 20 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.15% Nonidet P-40, 50 mM β-glycerophosphate, 10 mM NaF, and 5 mM Na3VO4) containing the protease inhibitor cocktail and centrifuged at 24 g for 5 min. The supernatants obtained from the homogenate are used to analyze IκB-a and phospho-IκB-a. For nuclear protein extraction, a nuclear lysis buffer (20 mM HEPES, pH 7.9,
Evidence-Based Complementary and Alternative Medicine

2.6. Western Blotting Analysis. The amount of proteins was quantified using the Bradford protein assay. Protein samples (20 μg/lane) were separated into 10% SDS-PAGE gel and transferred to poly(vinylidene fluoride) (PVDF) membranes. The membrane was blocked for 1 h in TBS containing 0.1% Tween (TBS-T) and 5% bovine serum albumin. The membrane was incubated overnight at 4°C with primary antibodies. The following antibodies were used in this study: β-actin (1:1000; cat. no. sc-7778; Santa Cruz Biotechnology), ERK1/2 (1:1000; cat. no. 4695S; Cell Signaling Technology), phospho-ERK1/2 (1:1000; cat. no. 4370S; Cell Signaling Technology), SAPK/JNK (1:1000; cat. no. 9252S; Cell Signaling Technology), phospho-SAPK/JNK (1:1000; cat. no. 293138; Santa Cruz Biotechnology), p38 (1:1000; cat. no. 3839S; Cell Signaling Technology), phospho-p38 (1:1000; cat. no. sc-166182; Santa Cruz Biotechnology), NF-κB (1:1000; cat. no. sc-293138; Santa Cruz Biotechnology), phospho-NF-κB (1:1000; cat. no. 9252S; Cell Signaling Technology), IκBα (1:1000; cat. no. sc-7977; Santa Cruz Biotechnology), IκBβ (1:1000; cat. no. sc-3034S; Cell Signaling Technology), and anti-rabbit IgG (1:4000; cat. no. sc-2027; Santa Cruz Biotechnology) and anti-mouse IgG (1:3000; cat. no. sc-11100; Santa Cruz Biotechnology) and anti-rabbit IgG (1:4000; cat. no. sc-11100; Santa Cruz Biotechnology) secondary antibodies were incubated room temperature for 1 h. The blots were visualized by Davinch-Chemi (cat no. CAS400 MF; Davinch-K, Seoul, Korea) with enhanced chemiluminescence kit (cat. no. ABC-3001; AbClon, Seoul, Korea).

2.7. Reverse Transcription Polymerase Chain Reaction (RT-PCR) Analysis. For RNA extraction, the lung tissues and raw 264.7 cells were homogenized in TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA), according to the manufacturer’s instructions. The optical density was read at a wavelength of 260 nm to quantify RNA. To synthesize complementary DNA, Maxime RT PreMix (Invitrogen) was mixed with 1 μg RNA at 45°C for 1 h and incubated at 95°C for 5 min. PCR was performed using Maxime PCR PreMix (Invitrogen) and synthesized cDNA template. The sequence of the primers used was as shown in Table 1. The amplification conditions were 94°C for 30 sec, followed by 40 cycles of 94°C for 1 min, range from 58 to 70°C for 30 sec, 72°C for 1 min and final extension at 72°C for 5 min. The relative expressions of gene were calculated and normalized to GAPDH and analyzed by ImageJ software.

2.8. Statistical Analysis. Significance was determined by one-way analysis of variance (ANOVA) and Tukey’s multiple comparison tests. In all analyses, p < 0.05 was taken to indicate statistical significance.

3. Results

3.1. Effects of SSHT on the Histological Analysis of Lung Tissue. Histological analysis was conducted to evaluate whether SSHT recovers LPS-induced change of lung structure. Compared to the structure of lung tissues in normal group, the LPS group led to alveolar hemorrhage, alveolar wall thickening, and alveolar spaces shrinkage. In contrast, SSHT treatment relieved alveolar wall thickness and alveolar spaces shrinkage similar to normal group (Figure 1(a)). The ALI score by LPS sensitization was 3 times higher than nontreated CTR group (p < 0.05). SSHT treatment at all concentrations (0.05, 0.55, and 5.55 g/kg) significantly decreased the histology scores by 34.5%, 46.2%, and 42.2% (p < 0.05), respectively, while DEX treatment showed 51.8% reduction (p < 0.05) of ALI score in LPS-sensitized mice (Figure 1(b)).

3.2. Effects of SSHT on Expression of Inflammatory Cytokines IL-6, TNF-α, and IFN-γ in Lung Tissues and Raw 264.7 Cells. To examine whether SSHT treatment inhibits LPS-induced inflammation in ALI model, proinflammatory cytokines IL-6, TNF-α, and interferon-γ (IFN-γ) in lung tissue was assessed by RT-PCR. Expression of IL-6 was increased 3.18 times (p < 0.05) in LPS-treated group compared to the normal group. SSHT treatment at the concentrations of 0.55 and 5.55 g/kg decreased expression of IL-6 to 34.1% and 55.4% of LPS-treated group, respectively (p < 0.05). The levels of TNF-α increased 3.56 times of LPS-treated group than that in the normal group (p < 0.05). Expression of TNF-α was decreased 58.5% in treated with 5.55 g/kg of SSHT (p < 0.05). In contrast, the other cytokine expression levels, expression of IFN-γ was 0.57 times decreased in LPS-treated group compared with the nontreated CTR group (p < 0.05). SSHT treatment with 5.55 g/kg increased the expression of IFN-γ 35.94% compared to LPS group (Figure 2(a)) (p < 0.05).

Additionally, the expressions of IL-6 and TNF-α in LPS-sensitized raw 264.7 cells were 2.8 and 3.0 times increased compared to nontreated cells (p < 0.05), while LPS significantly decreased the mRNA level of IFN-γ in raw 264.7 cells (p < 0.05). In the SSHT-treated cells in the presence of LPS, the expressions of IL-6 and TNF-α were markedly decreased. 500 and 1000 μg/mL of SSHT significantly inhibited the IL-6 levels, while 250, 500, and 1000 μg/mL of SSHT significantly reduced the TNF-α levels, respectively (p < 0.05). Moreover, 1000 μg/mL of SSHT significantly increased the IFN-γ expression in LPS-sensitized raw 264.7 cells (Figure 2(b)) (p < 0.05).

3.3. Effects of SSHT on NF-κB Translocation and IκB-α Phosphorylation in Lung Tissue. IκB-α/NF-κB pathway is a key regulator of inflammation and highly activated in ALI, while LPS treatment induced the increases of 1.24 times on phosphorylated IκB-α and 1.66 times on translocated NF-κB, respectively (p < 0.05). IκB-α phosphorylation was reduced 18.6% and 24.3% by 0.55 and 5.55 g/kg of SSHT treatment, respectively (Figure 3) (p < 0.05). Moreover,
expression of nuclear NF-κB was also decreased 63.5%, 67.9%, and 88.9% by SSHT treatment ($p < 0.05$).

### 3.4. Effects of SSHT on Expression of MAP Kinase in Lung Tissue

LPS-induced 1.36 times increase of ERK phosphorylation in lung tissues of mice ($p < 0.05$). Administration of SSHT at all concentrations (0.05, 0.55, and 5.55 g/kg) had significantly dose-dependently decreased the ERK phosphorylation by 13%, 26.4%, and 56.8% ($p < 0.05$). Phosphorylation of JNK was significantly increased by 2.65 times in LPS-treated group compared with the CTR group ($p < 0.05$), whereas 0.55 and 5.55 g/kg of SSHT treatment markedly reduced LPS-induced phosphorylated JNK by 33.7% and 41% ($p < 0.05$). In LPS-sensitized mice, phosphorylation of p38 was 1.12 times increased in comparison with normal mice ($p < 0.05$). SSHT 5.55 g/kg-treated group showed a significant 15.7% reduction of p38 phosphorylation ($p < 0.05$) (Figure 4).

### 4. Discussion

New finding of efficacy of medicine would be helpful to expand its medical indication as a prescription for health insurance. Recommended daily intake dose of SSHT to human is 9 g/day/60 kg, converted to 5.55 g/kg of SSHT in mice. In this study, 0.05, 0.55, and 5.55 g/kg of SSHT were administered to LPS-induced ALI mice. SSHT causes histological changes including alveolar hemorrhage, shrinkage of alveolar spaces, and alveolar wall thickening [25]. Those symptoms can be prevented by treatment with SSHT at a concentration of 5.55 g/kg.

_B. falcatum_ Linne polysaccharides, a major herb of SSHT, suppressed LPS-induced proinflammatory cytokines production including IL-6, IL-1β, IFN-β, and TNF-α in peritoneal macrophages of mice [26]. Additionally, baicalin derived from _S. baicalensis_ Georgi consisting of SSHT has been studied to decrease TNF-α and IL-1β levels in
bronchoalveolar lavage fluids of LPS-induced ALI mice [27]. Total saponin from Ginseng as another major herb of SSHT was reported to inhibit LPS-induced increase of serum TNF-α level [28]. Based on the previous evidence, we anticipated that SSHT has inhibitory effects against ALI by regulating proinflammatory cytokines. In particular, lung proinflammatory cytokine expressions such as IL-6, TNF-α, and IFN-γ in ALI model were investigated to find the underlying
mechanism of SSHT on the recovery of alveolar wall thickening. Proinflammatory cytokines such as IL-6 and TNF-α are considered key components of the acute inflammatory response [29–31]. Some studies have shown that TNF-α produced by initiating inflammatory response in macrophages undergo to activate NF-κB pathway and MAP kinase [32]. IL-6 is a multifunctional cytokine produced by monocytes and macrophages in the LPS-induced immune response [33]. IFN-γ as a primary activator by stimulating innate and adaptive immunity clears intracellular pathogens and produces enzymes to inhibit viral infections [34, 35]. IL-6 and TNF-α mRNA levels in the lung tissues and raw 264.7 cells were increased by exposure of LPS and significantly decreased by the pretreatment or cotreatment with SSHT. Those results demonstrate that SSHT might regulate the counterbalance of inflammatory responses by down-regulating IL-6 and TNF-α and upregulating IFN-γ. NF-κB is translocated from the cytoplasm to the nucleus by inflammatory cytokines such as IL-6 and TNF-α [36–40]. The nuclear translocation of NF-κB is regulated by IκB-α proteolytic degradation [41]. Additionally, MAP kinases including ERK1/2, SAPK/JNK, and p38 are associated with the production of cytokines in the inflammatory response [42]. Inhibition of NF-κB and MAP kinases in LPS-sensitized lung tissues could ameliorate ALI [43]. The expression of NF-κB and the phosphorylation of IκB-α in LPS-sensitized lung tissue were increased, but they were markedly decreased in the SSHT-treated mice. SSHT also significantly reduced the phosphorylation of ERK1/2, SAPK/JNK, and p38 in the lungs. In addition to the results from IL-6 and

![Figure 4: Expressions of MAP kinase of lung tissues indicated by western blot analysis. CTR: normal control group; LPS: LPS-sensitized ALI group; DEX: DEX-treated and LPS-sensitized group; S0.05: 0.05 g/kg SSHT-treated and LPS-sensitized group; S0.55: 0.55 g/kg SSHT-treated and LPS-sensitized group; and S5.55: 5.55 g/kg SSHT-treated and LPS-sensitized group. Results are presented as mean ± S.E.M. ### p < 0.001 compared with the CTR group; *** p < 0.001, ** p < 0.01, and * p < 0.05 compared with the LPS group.](image1)

![Figure 5: Schematic diagram of potential action of SSHT on lung inflammation. SSHT appears to regulate the IL-6, TNF-α, and IFN-γ, following the inhibition of NF-κB and MAP kinases expressions. These actions inhibit the LPS-induced lung inflammation in ALI.](image2)
TNF-α, SSHT attenuated the activation of MAP kinase and NF-κB by inhibition of inflammatory cytokines such as IL-6 and TNF-α (Figure 5).

5. Conclusion

In conclusion, SSHT alleviated the inflammatory IL-6 and TNF-α production, following the decreases of transcription factors including NF-κB and MAP kinases. Inhibition of inflammatory responses by SSHT in lung would be helpful to ameliorate LPS-induced ALI. Taken together, SSHT might be beneficial for treating ALI. Since the administration of 5.55 g/kg of SSHT to mice is converted to daily intake 9 g/day/60 kg dose for human, Jungwoo Pharmacy Sosihotang Soft Ext. is applicable for treating lung inflammation. Optimal dosage range of SSHT might be 9 g/day/60 kg, a daily intake dose for human in present. Further studies regarding the maximal efficacy and toxicity of SSHT are needed.

Abbreviations

ALI: Acute lung injury
HED: Human equivalent dose
IFN-γ: Interferon-γ
IL: Interleukin
LPS: Lipopolysaccharide
MAP: Mitogen-activated protein
SSHT: Sosihotang
TNF-α: Tumor necrosis factor-α.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by a grant of the National Development Institute of Korean Medicine (NIKOM) funded by the Korean Ministry of Health and Welfare (MOHW), Republic of Korea.

References

[1] A. Dulu, S. M. Pastores, B. Park, E. Riedel, V. Rusch, and N. A. Halpern, “Prevalence and mortality of acute lung injury and ARDS after lung resection,” Chest, vol. 130, no. 1, pp. 73–78, 2006.
[2] D. Parekh, R. C. Dancer, and D. R. Thickett, “Acute lung injury,” Clinical Medicine, vol. 11, no. 6, pp. 615–618, 2011.
[3] L. Fan, Y. Fan, L. Liu et al., “Chelerythrine attenuates the inflammation of lipopolysaccharide-induced acute lung inflammation through NF-kappaB signaling pathway mediated by Nrf2,” Frontiers in Pharmacology, vol. 9, p. 1047, 2018.
[4] L.-M. Zhang, J. Zhang, Y. Zhang et al., “Interleukin-18 binding protein attenuates lipopolysaccharide-induced acute lung injury in mice via suppression NF-κB and activation Nrf2 pathway,” Biochemical and Biophysical Research Communications, vol. 505, no. 3, pp. 837–842, 2018.
[5] G.-F. Zhu, H.-J. Guo, Y. Huang, C.-T. Wu, and X.-F. Zhang, “Eriodictyol, a plant flavonoid, attenuates LPS-induced acute lung injury through its antioxidative and anti-inflammatory activity,” Experimental and Therapeutic Medicine, vol. 10, no. 6, pp. 2259–2266, 2015.
[6] Y. Luo, X. X. Pang, A. R. Ansari et al., “Visfatin exerts immunomodulatory effects in lipopolysaccharide-induced acute lung injury in murine model,” Inflammation, vol. 43, no. 1, pp. 109–122, 2020.
[7] S. A. Lee, S. H. Lee, J. Y. Kim, and W. S. Lee, “Effects of glycyrrhizin on lipopolysaccharide-induced acute lung injury in a mouse model,” Journal of Thoracic Disease, vol. 11, no. 4, pp. 1287–1302, 2019.
[8] R. B. Goodman, J. Pugin, J. S. Lee, and M. A. Matthay, “Cytokine-mediated inflammation in acute lung injury,” Cytokine and Growth Factor Reviews, vol. 14, no. 6, pp. 523–535, 2003.
[9] Z. Zhang, L. Chen, and H. Ni, “The effectiveness of Corticosteroids on mortality in patients with acute respiratory distress syndrome or acute lung injury: a secondary analysis,” Sci Rep, vol. 5, Article ID 17654, 2015.
[10] E. N. Deal, J. M. Hollands, G. E. Schramm, and S. T. Micek, “Role of corticosteroids in the management of acute respiratory distress syndrome,” Clinical Therapeutics, vol. 30, no. 5, pp. 787–799, 2008.
[11] D. Mokra, P. Mikolka, P. Kosutova, and J. Mokry, “Corticosteroids in acute lung injury: the dilemma continues,” International Journal of Molecular Sciences, vol. 20, p. 19, 2019.
[12] C. S. Calfee and M. A. Matthay, “Nonventilatory treatments for acute lung injury and ARDS,” Chest, vol. 131, no. 3, pp. 913–920, 2007.
[13] G. R. Sethi and K. K. Singhal, “Pulmonary diseases and corticosteroids,” The Indian Journal of Pediatrics, vol. 75, no. 10, pp. 1045–1056, 2008.
[14] M. J. Lan and X. D. He, “Prone positioning ventilation for treatment of acute lung injury and acute respiratory distress syndrome,” Chinese Journal of Traumatology = Zhonghua Chuang Shang Za Zhi, vol. 12, no. 4, pp. 238–242, 2009.
[15] W. J. Mach, A. R. Thimmesch, J. T. Pierce, and J. D. Pierce, “Consequences of hypoxia and the toxicity of oxygen in the lung,” Nursing Research and Practice, vol. 2011, Article ID 260482, 7 pages, 2011.
[16] K. Kayano, I. Sakaida, K. Uchida, and K. Okita, “Inhibitory effects of the herbal medicine Sho-saiko-to (TJ-9) on cell proliferation and procollagen gene expressions in cultured rat hepatic stellate cells,” Journal of Hepatology, vol. 29, no. 4, pp. 642–649, 1998.
[17] H. M. Kim, Y. Y. Kim, H. Y. Jang, S. J. Moon, and N. H. An, “Action of sosihotang on systemic and local anaphyls by anal administration,” Immunopharmacology and Immunotoxicology, vol. 21, no. 3, pp. 635–643, 1999.
[18] Y. C. Oh, W. K. Cho, Y. H. Jeong et al., “Anti-inflammatory effect of Sosihotang via inhibition of nuclear factor-kappaB and mitogen-activated protein kinases signaling pathways in lipopolysaccharide-stimulated RAW 264.7 macrophage cells,” Food and Chemical Toxicology, vol. 53, pp. 343–351, 2012.
[19] N. Ohtake, R. Suzuki, H. Daikuhera et al., “Modulation of lung local immune responses by oral administration of a
Eviden
ces-Based Complementary and Alternative Medicine

eral medicine Sho-saiko-to,” *International Journal of Immunopharmacology*, vol. 22, no. 6, pp. 419–430, 2000.
[20] M. Nose, K. Terawaki, N. Iwashashi, K. Oguri, and Y. Oghara, “Comparative study of the high molecular mass fraction and low molecular mass fraction of Sho-saiko-to in a murine immunologically induced liver injury model,” *Biological and Pharmaceutical Bulletin*, vol. 25, no. 1, pp. 64–67, 1997.
[21] M. Kusunose, B. Qiu, T. Cui et al., “Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethyl-
nitrosamine induced liver injury rats,” *Biological and Pharmaceutical Bulletin*, vol. 25, no. 11, pp. 1417–1421, 2002.
[22] N. Ohtake, Y. Nakai, M. Yamamoto et al., “I" he herbal

[23] N. Parameswaran and S. Patial, “Tumor necrosis factor-

[24] M. Kusunose, B. Qiu, T. Cui et al., “Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethyl-
nitrosamine induced liver injury rats,” *Biological and Pharmaceutical Bulletin*, vol. 25, no. 11, pp. 1417–1421, 2002.
[25] M. Kusunose, B. Qiu, T. Cui et al., “Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethyl-
nitrosamine induced liver injury rats,” *Biological and Pharmaceutical Bulletin*, vol. 25, no. 11, pp. 1417–1421, 2002.
[26] N. Ohtake, Y. Nakai, M. Yamamoto et al., “I" he herbal

[27] N. Parameswaran and S. Patial, “Tumor necrosis factor-

[28] K. M. Kim, H. J. Kim, J. Ryu, and D. H. Sohn, “Ginseng

[29] K. V. Ramana, A. A. Fadl, R. Tammaili, A. B. M. Reddy, A. K. Chopra, and S. K. Srivastava, “Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages,” *Journal of Biological Chemistry*, vol. 281, no. 44, pp. 33019–33029, 2006.
[30] J.-M. Zhang and J. An, “Cytokines, inflammation, and pain,” *International Anesthesiology Clinics*, vol. 45, no. 2, pp. 27–37, 2007.
[31] L. W. Soromou, Z. Zhang, R. Li et al., “Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin,” *Molecules*, vol. 17, no. 3, pp. 3574–3585, 2012.
[32] N. Parameswaran and S. Patial, “Tumor necrosis factor-α signaling in macrophages,” *Critical Reviews in Eukaryotic Gene Expression*, vol. 20, no. 2, pp. 87–103, 2010.
[33] A. Rubini, “Interleukin-6 and lung inflammation: evidence for a causative role in inducing respiratory system resistance increments,” *Inflammation and Allergy-Drug Targets*, vol. 12, no. 5, pp. 315–321, 2013.
[34] M. Akdis, S. Burgler, R. Cramer et al., “Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases,” *Journal of Allergy and Clinical Immunology*, vol. 127, no. 3, pp. 701–721, 2011.
[35] H. Mühl and J. Pfeilschifter, “Anti-inflammatory properties of pro-inflammatory interferon-γ,” *International Immunopharmacology*, vol. 3, no. 9, pp. 1247–1255, 2003.
[36] M. B. Everhart, W. Han, T. P. Sherrill et al., “Duration and intensity of NF-κB activity determine the severity of endo-

[37] B. Kaminska, “MAPK signalling pathways as molecular tar-
gets for anti-inflammatory therapy--from molecular mecha-
nisms to therapeutic benefits,” *Biochimica et Biophysica Acta*, vol. 1754, no. 1-2, pp. 253–262, 2005.
[38] S. Liu, G. Feng, G.-l. Wang, and G.-j. Liu, “p38MAPK inhi-
bition attenuates LPS-induced acute lung injury involvement of NF-κB pathway,” *European Journal of Pharmacology*, vol. 584, no. 1, pp. 159–165, 2008.
[39] P. Moine, R. McIntyre, M. D. Schwartz et al., “NF-κB reg-
ulatory mechanisms IN alveolar macrophages from patients with acute respiratory distress syndrome,” *Shock*, vol. 13, no. 2, pp. 85–91, 2000.
[40] K. Schulze-Osthoff, D. Ferrari, K. Riehemann, and S. Wesselborg, “Regulation of NF-κB activation by MAP kinase cascades,” *Immunobiology*, vol. 198, no. 1-3, pp. 35–49, 1997.
[41] M. Karin, “How NF-κB is activated: the role of the IκB kinase (IKK) complex,” *Oncogene*, vol. 18, no. 49, pp. 6867–6874, 1999.
[42] W. Zhong, Y. Cui, Q. Yu et al., “Modulation of LPS-stimulated pulmonary inflammation by Borneol in murine acute lung injury model,” *Inflammation*, vol. 37, no. 4, pp. 1148–1157, 2014.
[43] P. Sun, K. Zhou, S. Wang et al., “Involvement of MAPK/NF-

[44] B kinase B is activated: the role of the IκB kinase (IKK) complex,” *Oncogene*, vol. 24, no. 2, pp. 79–82, 2013.
[45] K. V. Ramana, A. A. Fadl, R. Tammaili, A. B. M. Reddy, A. K. Chopra, and S. K. Srivastava, “Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages,” *Journal of Biological Chemistry*, vol. 281, no. 44, pp. 33019–33029, 2006.
[46] J.-M. Zhang and J. An, “Cytokines, inflammation, and pain,” *International Anesthesiology Clinics*, vol. 45, no. 2, pp. 27–37, 2007.
[47] L. W. Soromou, Z. Zhang, R. Li et al., “Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin,” *Molecules*, vol. 17, no. 3, pp. 3574–3585, 2012.
[48] N. Parameswaran and S. Patial, “Tumor necrosis factor-α signaling in macrophages,” *Critical Reviews in Eukaryotic Gene Expression*, vol. 20, no. 2, pp. 87–103, 2010.
[49] A. Rubini, “Interleukin-6 and lung inflammation: evidence for a causative role in inducing respiratory system resistance increments,” *Inflammation and Allergy-Drug Targets*, vol. 12, no. 5, pp. 315–321, 2013.
[50] M. Akdis, S. Burgler, R. Cramer et al., “Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases,” *Journal of Allergy and Clinical Immunology*, vol. 127, no. 3, pp. 701–721, 2011.